About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Deadliest Malaria Parasite Wiped Out by Starving It to Death

by Kathy Jones on December 10, 2011 at 7:39 PM
Font : A-A+

 Deadliest Malaria Parasite Wiped Out by Starving It to Death

Research has demonstrated that a newly developed anti-malarial agent clears infections caused by the malaria parasite most lethal to humans by literally starving the parasites to death.

The drug BCX4945 developed by researchers at Albert Einstein College of Medicine of Yeshiva University could bolster efforts to develop more potent therapies against one of the world's leading killers.lasmodium falciparum, the malaria species most likely to cause severe infections and death, is very common in many countries in Africa south of the Sahara desert.

Advertisement

The Einstein researchers led by Vern Schramm, Ph.D., professor and Ruth Merns Chair in Biochemistry exploited what is arguably P. falciparum's Achilles' heel: it can't synthesize purines, vital building blocks for making DNA.

Instead, the parasite must make purines indirectly, by using an enzyme called purine nucleoside phosphorylase (PNP) to make a purine precursor called hypoxanthine.
Advertisement

By inhibiting PNP, the drug BCX4945 kills the parasites by starving them of the purines they need to survive.

After BCX4945 showed potency against laboratory cultures of P. falciparum, owl monkeys were chosen as the non-human primate model for further testing of the drug.

Three animals were infected with a strain of P. falciparum that is consistently lethal without anti-malarial therapy.

Orally administering BCX4945 twice a day for seven days cleared the infections from all the animals between the fourth and seventh day of treatment. The monkeys remained parasite-negative for up to nine days post-treatment.

Parasitic infection eventually returned in all three monkeys after treatment ended, although a lower rate of parasitic growth was observed. No signs of toxicity were observed during the study period (30 days after the first dose).

"Inhibiting PNP differs from all other current approaches for treating malaria," said Dr. Schramm.

"For that reason, BCX4945 fits well with the current World Health Organization protocols for malaria treatment, which call for using combination-therapy approaches against the disease," he added.

The study was published in the November 11, 2011 issue of PLoS ONE.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Malaria-water Tapeworm Infections Malaria Mosquito Diseases Trypanosomiasis Death Facts Fever Malaria - Protection Strategies 

Most Popular on Medindia

Iron Intake Calculator How to Reduce School Bag Weight - Simple Tips Blood Pressure Calculator Diaphragmatic Hernia Selfie Addiction Calculator Blood Donation - Recipients Find a Doctor Sinopril (2mg) (Lacidipine) Loram (2 mg) (Lorazepam) Turmeric Powder - Health Benefits, Uses & Side Effects
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Deadliest Malaria Parasite Wiped Out by Starving It to Death Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests